Cascadian Therapeutics (FRA:3O61) ROCE % : -58.92% (As of Dec. 2017)

View and export this data going back to . Start your Free Trial

What is Cascadian Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cascadian Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2017 was -58.92%.

Cascadian Therapeutics ROCE % Historical Data

The historical data trend for Cascadian Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cascadian Therapeutics ROCE % Chart

Cascadian Therapeutics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

ROCE %

Get a 7-Day Free Trial

-50.51

-61.81

-36.64

-79.37

-60.31

Cascadian Therapeutics Quarterly Data
	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17
ROCE %	Get a 7-Day Free Trial															-55.06	-40.69	-40.40	-42.38	-58.92

Cascadian Therapeutics ROCE % Calculation

Cascadian Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2017 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2017 )		(A: Dec. 2016 )		(A: Dec. 2017 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2017 )		(A: Dec. 2016 )		(A: Dec. 2017 )
	=	-49.085	/	( ( (78.935 - 8.317)	+	(102.097 - 9.936) )	/ 2 )
	=	-49.085	/	( (70.618	+	92.161)	/ 2 )
	=	-49.085	/	81.3895
	=	-60.31 %

Cascadian Therapeutics's ROCE % of for the quarter that ended in Dec. 2017 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2017 )		(Q: Sep. 2017 )		(Q: Dec. 2017 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2017 )		(Q: Sep. 2017 )		(Q: Dec. 2017 )
	=	-57.96	/	( ( (111.912 - 7.327)	+	(102.097 - 9.936) )	/ 2 )
	=	-57.96	/	( ( 104.585	+	92.161 )	/ 2 )
	=	-57.96	/	98.373
	=	-58.92 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2017) EBIT data.

Cascadian Therapeutics (FRA:3O61) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cascadian Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Cascadian Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cascadian Therapeutics (FRA:3O61) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (FRA:3O61) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cascadianrx.com

Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.

Cascadian Therapeutics (FRA:3O61) Headlines

No Headlines